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A heterologous prime-boost strategy using plasmid DNA, followed by replication-defective recombinant
adenovirus 5, is being proposed as a powerful way to elicit CD4 and CD8 T-cell-mediated protective
immunity against intracellular pathogens. We confirmed this concept and furthered existing research by
providing evidence that the heterologous prime-boost regimen using the gene encoding amastigote surface
protein 2 elicited CD4 and CD8 T-cell-mediated protective immunity (reduction of acute parasitemia and
prolonged survival) against experimental infection with Trypanosoma cruzi. Protective immunity correlated
with the presence of in vivo antigen-specific cytotoxic activity prior to challenge. Based on this, our second goal
was to determine the outcome of infection after heterologous prime-boost immunization of perforin-deficient
mice. These mice were highly susceptible to infection. A detailed analysis of the cell-mediated immune
responses in immunized perforin-deficient mice showed an impaired gamma interferon (IFN-) secretion by
immune spleen cells upon restimulation in vitro with soluble recombinant antigen. In spite of a normal
numeric expansion, specific CD8 T cells presented several functional defects detected in vivo (cytotoxicity)
and in vitro (simultaneous expression of CD107a/IFN- or IFN-/tumor necrosis factor alpha) paralleled by
a decreased expression of CD44 and KLRG-1. Our final goal was to determine the importance of IFN- in the
presence of highly cytotoxic T cells. Vaccinated IFN--deficient mice developed highly cytotoxic cells but failed
to develop any protective immunity. Our study thus demonstrated a role for perforin and IFN- in a number
of T-cell-mediated effector functions and in the antiparasitic immunity generated by a heterologous plasmid
DNA prime-adenovirus boost vaccination strategy.
Genetic vaccination using naked DNA or recombinant vi-
ruses is being pursued as alternative vaccines. This strategy can
be particularly important in the case of intracellular pathogens
and neoplasic cells when the effectiveness relies heavily on the
vaccination’s capacity to elicit specific immune responses me-
diated by cytotoxic CD8 T cells (reviewed in references 27,
48, and 49). One of the most prolific areas of genetic vaccina-
tion development is the strategy known as the heterologous
prime-boost regimen. This consists in the use of two different
vectors both carrying a gene that encodes the same antigenic
protein for priming and boosting immunizations. This strategy
was first proposed in the early 1990s using a combination of
recombinant viruses (influenza and vaccinia viruses) to induce
protective immunity against malaria (34, 50). Subsequently,
this approach was extended and simplified by incorporating
naked DNA priming, followed by a booster injection of a
recombinant poxviral vector (i.e., modified vaccinia Ankara);
this was also used to generate sterile protective immunity in
rodent malaria (53, 54). Collectively, these studies demon-
strated that the heterologous prime-boost regimen proved
more effective than the repeated use of any of these vectors
individually. In subsequent years, the heterologous plasmid
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DNA prime-poxvirus vector boost regimen was adopted world-
wide as a powerful mean to elicit strong effector CD8 Tc1-
mediated immune responses against viral, parasitic, and neo-
plastic antigens in rodents and nonhuman primates (4;
reviewed in references 29, 44, and 65). Based on the preclinical
studies, a number of clinical human trials have also been ini-
tiated. However, to our knowledge, heterologous prime-boost
regimens using plasmid DNA and recombinant poxviruses
have not yet provided meaningful protective immunity to hu-
mans (21, 28, 42, 45).
Although there are a number of possible vector combina-
tions that significantly improve cell-mediated immunity, par-
ticularly of specific CD8 T cells, heterologous prime-boost
vaccination using naked plasmid DNA for priming, followed by
a booster injection of recombinant replication-deficient ade-
novirus 5 has recently received significant attention. This strat-
egy has proved successful in some relevant experimental mod-
els such as simian immunodeficiency virus and malaria,
providing considerable protective immunity (2, 13, 14, 26, 33,
41, 62).
The fact that protective CD8 T cells could be induced in
mice and nonhuman primates against both virus and parasites
made it an interesting strategy against other microbial infec-
tions. We initially attempted to build on this strategy by gen-
erating protective CD4 Th1 and cytotoxic CD8 T cells against
the infection with a human intracellular protozoan parasite,
Trypanosoma cruzi. Both CD4 and CD8 T cells were de-
scribed as critical for acquired immunity against experimental
infection with T. cruzi (38, 39, 56–59). Vaccination studies
confirmed these observations by providing evidence that CD8
T cells are particularly important to the development of pro-
tective immunity in mice immunized with recombinant plasmid
DNA, proteins, or viruses (6, 19, 25, 31, 37, 43, 60). In addition
to CD8 T cells, CD4 Th1 cells also play a role in immunity
against T. cruzi after vaccination with plasmid DNA or recom-
binant protein (19, 30, 60).
In our previous studies, we showed that multiple immuniza-
tions of highly susceptible A/Sn mice with a gene or a recom-
binant protein based on the amastigote surface protein 2
(ASP-2) of T. cruzi generated protective immunity against a
lethal challenge with this parasite (6, 17, 19, 55, 60). In both
cases, vaccinated animals depleted of CD8 T cells prior to
challenge became highly susceptible to infection (6, 60). Pro-
tective CD8 T cells were directed to the immunodominant
epitope TEWETGQI located within amino acids 320 to 327 of
ASP-2 (6, 19).
The present study was designed first to evaluate whether we
could reduce the number of immunizing doses required to
generate CD4 and CD8 T-cell-mediated protective immu-
nity using a heterologous prime-boost regimen. A reduction in
the number of doses may greatly improve the feasibility of
human vaccination trials. The fact that mice immunized with
recombinant AdASP-2 showed the highest levels of in vivo
cytotoxicity mediated by CD8 T cells prior to challenge, and
some degree of protective immunity led us to study the role for
perforin during vaccination. Subsequently, we determined
whether the high susceptibility observed in perforin-deficient
mice correlated with impaired effector T-cell immune re-
sponses and the expression of relevant activation markers by
specific CD8 T cells. Our final goal was to determine the
importance of gamma interferon (IFN-), a critical mediator
of adaptive immunity against T. cruzi infection, for protective
immunity in the presence of highly cytotoxic T cells.
MATERIALS AND METHODS
Mice and parasites. Female 5- to 8-week-old A/Sn, C57BL/6 wild-type (WT),
C57BL/6 perforin-deficient (perforin KO), C57BL/6 CD4 deficient (CD4 KO),
C57BL/6 CD8a-deficient (CD8 KO), or C57BL/6 IFN--deficient (IFN- KO)
mice were purchased from University of Sa˜o Paulo, raised at the Instituto de
Biofísica Carlos Chagas Filho or at the animal facilities of the Oswaldo Cruz
Foundation. Parasites of the Y strain of T. cruzi were used here (10). Blood-
stream trypomastigotes were obtained from mice infected 7 days earlier. The
concentration of parasites was estimated and adjusted to 750 parasites/ml. Each
A/Sn mouse was inoculated intraperitoneally (i.p.) with 0.2 ml. In the case of
C57BL/6 or perforin KO mice, the concentration of parasites was estimated and
adjusted to 5  104/ml, and 0.2 ml was injected i.p. (104 trypomastigotes/mouse).
Parasite development was monitored by counting the number of bloodstream
trypomastigotes in 5 l of fresh blood collected from the tail vein (10). Hemocul-
tures were performed with aliquots of 0.1 ml of blood collected and cultured at
28°C for 1 month in 5 ml of axenic liver infusion tryptose medium. Parasite
growth was monitored microscopically every week. For PCR, DNA was extracted
from 0.1 ml of blood and resuspended in a final volume of 100 l. As controls,
known numbers of T. cruzi Y strain blood trypomastigotes were diluted in 0.1 ml
of blood obtained from naive mice (200, 100, 50, 25, 12.5, or 0 trypomastigotes/
ml). Then, 5-l portions were used for PCRs with Platinum Taq DNA polymer-
ase (Invitrogen) and the T. cruzi kDNA primers S35 (5-AAATAATGTACGG
GGGAGATGCATGA-3) and S36 (5-GGGTTCGATTGGGGTTGGTGT-3).
The amplification cycles consisted of an initial denaturation of 5 min at 94°C,
followed by 35 cycles of 30 s at 95°C (denaturation), 30 s at 62°C (primer
annealing), and 1 min at 72°C (primer extension). We observed a 330-bp band in
samples containing as few as 12.5 trypomastigotes/ml, but not in parasite-free
blood DNA. Mouse survival was monitored daily. The use of animals and the
experimental procedures were approved by the Ethics Committee for Animal
Care of the Federal University of Sa˜o Paulo.
Peptide synthesis. Peptides VNHRFTLV and TEWETGQI were prepared by
standard N[9-fluorenylmethyloxycarbonyl] on a PSSM8 multispecific peptide
synthesizer (Shimadzu, Kyoto, Japan) by solid-phase synthesis with a scale of 30
mol. Peptide was purified by high-pressure liquid chromatography in a Shi-
madzu system. Peptides were analyzed in a C18 Vydac column (10 by 250 mm,
5-m particle diameter). The peptide purity was in a range of 80 to 90% purity.
Their identities were confirmed by Q-TOF Micro equipped with an electrospray
ionization source (Micromass, United Kingdom). Pentamer H-2Kb/VNHRFTLV
was purchased from ProImmune, Inc. (Oxford, United Kingdom).
Recombinant plasmids and adenoviruses used for immunization. Plasmid
pIgSPclone9 was obtained by inserting into the commercial vector pcDNA3
(Invitrogen) the sequence encoding the signal peptide of mouse immunoglobulin
kappa chain in-frame with the gene encoding T. cruzi ASP-2 (10). pAdCMV-
ASP2 is an adenoviral transfer plasmid that contains a eukaryotic expression
cassette formed by the cytomegalovirus immediate-early promoter and the sim-
ian virus 40 RNA polyadenylation sequences. Inside this cassette we cloned the
DNA sequences encoding T. cruzi ASP-2 obtained by restriction digestion of
plasmid pIgSPclone9 (AdASP-2 [37]). Viruses and plasmids were purified as
described earlier, and they both lead to expression of the antigen as evaluated by
in vitro transfections (10, 37). Mice were inoculated intramuscularly (i.m.) in
each tibialis anterioris muscle with 50 g of plasmid DNA. Twenty-one days
later, these mice received in these same spots 50 l of viral suspension containing
108 PFU of adenovirus. Immunological assays were performed 14 days after viral
inoculation.
In vivo depletion of CD4 T cells were performed by treating vaccinated A/Sn
or C57BL/6 mice with monoclonal antibody (MAb) GK1.5. At days 6, 4, and 2
before challenge with trypomastigotes, mice were injected i.p. with a dose of 0.5
mg of anti-CD4 or control rat immunoglobulin G (IgG). At 7 and 14 days
postchallenge, each mouse received one more dose of 0.5 mg of anti-CD4 or rat
IgG. As determined by fluorescence-activated cell sorting (FACS) analyses, the
efficacy of depletion of CD4 spleen cells before challenge was of 99.94% in
anti-CD4 treated mice compared to rat IgG-treated ones. In vivo depletion of
CD8 T cells were performed by treating vaccinated A/Sn mice with MAb 53.6.7.
At days 3 and 4 before challenge with trypomastigotes, mice were injected i.p.
with a dose of 1 mg of anti-CD8 or control rat IgG. At 7 days after challenge,
each mouse received one more dose of 1 mg of anti-CD8 or rat IgG. The efficacy
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of depletion of CD8 spleen cells before challenge was more than 96% in
anti-CD8-treated mice compared to rat IgG-treated ones.
Immunological assays. For the in vivo cytotoxicity assays, splenocytes collected
from naive A/Sn or C57BL/6 mice were treated with ACK buffer (0.15 M NH4Cl,
10 mM KHCO3, 0.1 mM disodium EDTA [pH 7.4]) to lyse the red blood cells.
These cells were divided into two populations and labeled with the fluorogenic
dye carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes,
Eugene, OR) at a final concentration of 5 M (CFSEhigh) or 0.5 M (CFSElow).
CFSEhigh cells were coated for 40 min at 37°C with a 1 or 2.5 M concentration
of the H-2Kb or H-2Kk ASP-2 peptides VNHRFTLV or TEWETGQI, respec-
tively. CFSElow cells remained uncoated. Then, CFSEhigh cells were washed and
mixed with equal numbers of CFSElow cells before 3  107 to 4  107 total cells
per mouse were injected intravenously. Recipient animals were mice previously
immunized with recombinant plasmids or adenoviruses or both. Spleen cells of
recipient mice were collected 4 h or 20 h after transfer, as indicated in the figure
legends, fixed with 1.0% paraformaldehyde, and analyzed by FACS using a
FacsCanto flow cytometer (BD, Mountain View, CA). The percent specific lysis
was determined by using the formula: [1  (% CFSEhigh immunized/% CFSElow
immunized)/(% CFSEhigh naive/% CFSElow naive)]  100. IFN- secretion by
cultured spleen cells and enzyme-linked immunospot (ELISPOT) assay for enu-
meration of IFN- producing cells was performed essentially as described pre-
viously (10, 50).
For flow cytometry analyses, we used mouse splenocytes treated with ACK
buffer. Single-cell suspensions were washed in phosphate-buffered saline (PBS),
stained for 10 min at room temperature with biotinylated major histocompati-
bility complex class I (MHC-I) multimer H-Kb/VNHRFTLV, and then stained
30 min at 4°C with avidin-phycoerythrin (PE)- and allophycocyanin (APC)-
labeled anti-CD8 antibodies (both from BD Pharmingen). For the analyses of
other cell surface markers, single cell suspension from spleens of mice were
depleted of erythrocytes, and CD8 T cells were purified by negative selection
using a MACS separation system (Miltenyi Biotec, Bergisch Gladbach, Ger-
many) according to the manufacturer’s protocols with magnetic LS columns. As
estimated by FACS analysis, 85% of the cells were CD8 T cells after enrich-
ment. These cells were stained at room temperature with biotinylated MHC-I
multimer H-Kb/VNHRFTLV and then stained 20 min at room temperature with
avidin-PE- and APC-labeled anti-CD8 antibodies, as well as with fluorescein
isothiocyanate (FITC)-labeled anti-CD11a, anti-CD43, anti-CD44, anti-CD62L,
anti-CD127, and anti-KLRG-1 antibodies (all from BD Pharmingen). At least
100,000 cells were acquired on a FacsCanto flow cytometer and then analyzed
with FlowJo (Tree Star) using a biexponential transform.
The expression of CD107a was evaluated after in vitro culture of splenocytes
in the presence or absence of antigenic stimulus. Cells were washed three times
in plain RPMI and resuspended in cell culture medium consisting of RPMI 1640
medium (pH 7.4) supplemented with 10 mM HEPES, 0.2% sodium bicarbonate,
59 mg of penicillin/liter, 133 mg of streptomycin/liter, and 10% HyClone fetal
bovine serum (HyClone, Logan, UT). The viability of the cells was evaluated by
using 0.2% trypan blue exclusion dye to discriminate between live and dead cells.
The cell concentration was adjusted to 5  106 cells/ml in cell culture medium
containing also anti-CD28 (2 g/ml), brefeldin A (10 g/ml), monensin (5 g/
ml), and the FITC-labeled anti-CD107a (2 g/ml, all from BD Pharmingen). In
half of the cultures, a final concentration of 10 M VNHRFTLV peptide was
added. The cells were cultivated in flat-bottom 96-well plates (Corning) in a final
volume of 200 l in duplicate at 37°C in a humid environment. After 12 h of
incubation, cells were stained for surface marker with anti-CD8 on ice for 20 min.
At least 100,000 cells were acquired on a FacsCanto flow cytometer and then
analyzed with FlowJo.
To detect IFN-, tumor necrosis factor alpha (TNF-), and interleukin-2
(IL-2) by intracellular staining (ICS), in vitro cultures of splenocytes were pre-
pared as described above; however, the culture medium used contained neither
monensin nor anti-CD107a. After 12 h of incubation, cells were stained for a
surface marker with anti-CD8 for 20 min on ice. The cells were then washed
twice in buffer containing PBS, 0.5% bovine serum albumin, and 2 mM EDTA;
fixed in 4% PBS-paraformaldehyde solution for 10 min; and permeabilized for 15
min in a PBS–0.1% bovine serum albumin–0.1% saponin solution. After being
washed twice, cells were stained for intracellular markers using APC-Cy7 anti-
CD3, PE-Cy7 anti-IFN-, Alexa 488-anti-TNF-, and APC-anti-IL-2 for 20 min
on ice. Finally, the cells were washed twice and fixed in 1% PBS-paraformalde-
hyde. At least 300,000 cells were acquired on a FacsCanto flow cytometer and
then analyzed with FlowJo.
Statistical analysis. The values of parasitemia of each individual mouse were
log transformed before being compared by one-way analysis of variance, fol-
lowed by Tukey HSD tests (available at http://faculty.vassar.edu/lowry
/VassarStats.html). The in vivo ELISPOT cytotoxicity assay results, the numbers
of multimer-positive cells, and the percentages of cytokine- or CD107a-express-
ing cells are expressed as medians (bars) and individual sample values (dots) in
the figures and were compared by using the nonparametric Mann-Whitney or
Kruskall-Wallis tests. The log-rank test was used to compare mouse survival rate
after challenge with T. cruzi. The differences were considered significant when
the P value was 	0.05.
RESULTS
Protective immunity of highly susceptible A/Sn mice after
vaccination with replication-defective recombinant adenovirus
type 5 expressing T. cruzi ASP-2. In earlier studies we observed
that protective immunity, as measured by reduction in the peak
parasitemia and delayed mouse mortality, required three doses
of plasmid DNA or recombinant protein (6, 17, 19). To deter-
mine whether protective immunity could be elicited by two
immunizing doses, we compared different protocols of vacci-
nation using either homologous or heterologous prime-boosting
regimens. The homologous protocols consisted of two immuniz-
ing doses of either plasmid DNA (pIgSPCl.9) or a recombinant
replication-defective adenovirus type 5 (AdASP-2) containing the
gene encoding ASP-2 of T. cruzi (6, 19, 60). The heterologous
immunization regimen consisted of a priming immunization with
pIgSPCl.9 followed by a booster injection of the AdASP-2. Si-
multaneously, a group of mice was injected with a single immu-
nizing dose of AdASP-2.
Immunized mice were challenged with a lethal dose of T.
cruzi bloodstream trypomastigotes after a short (14-day) or a
long (98-day) period after the final immunizing dose. As shown
in Fig. 1B, vaccination with two doses of pIgSPCl.9 failed to
reduce the magnitude of the peak parasitemia (day 11) com-
pared to control mice injected with pcDNA3 followed by re-
combinant Ad
-gal. Mice immunized with one or two doses of
AdASP-2 displayed a peak parasitemia 3.34- or 13.61-fold
lower than that of control mice (n 6, P	 0.01 in both cases).
The best reduction of the peak parasitemia was observed in the
group of mice vaccinated with the heterologous DNA prime-
recombinant adenovirus boost regimen (22.88-fold reduction
compared to controls, n  6, P 	 0.01).
When mouse survival was tracked after challenge (as shown
on Fig. 1C), the results from the parasitemia were mainly
confirmed. All three mouse groups immunized with AdASP-2
survived longer than control animals or mice immunized with
two doses of pIgSPCl.9. However, mouse survival differed sig-
nificantly among groups of mice immunized with two doses of
AdASP-2 compared to animals injected only once (P 	 0.001).
Protective immunity in both groups of mice boosted with the
recombinant AdASP-2 was high. No significant difference was
observed among the mouse groups primed with pIgSPCl.9 or
AdASP-2 (P  0.05). Based on these results, we selected the
heterologous prime-boost vaccination regimen to further re-
search the protective cells.
Protective immunity elicited by the heterologous prime-
boost regimen (pIgSPCl.9/AdASP-2) was stable at least until
98 days after the final immunizing dose. In ASP-2-immunized
mice challenged 14 or 98 days after the final boost vaccination,
the values of parasitemia were 16.70- or 31.41-fold lower than
control mice, respectively (Fig. 1E, P 	 0.01 in both cases).
However, no difference was recorded during the peak para-
sitemia between the two groups of ASP-2-immunized mice
(P  0.05). Similarly, ASP-2-vaccinated mice challenged 14 or
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FIG. 1. Trypomastigote-induced parasitemia and mortality in A/Sn mice immunized with different combinations of plasmid DNA and/or
replication defective human adenovirus type 5 expressing the ASP-2 of T. cruzi. (A) A/Sn mice were immunized as described. Priming and boosting
immunizations were performed with the indicated plasmid or adenovirus i.m. at 0 and 3 weeks, respectively. Two weeks after the final immunizing
dose, mice were challenged i.p. with 150 bloodstream trypomastigotes. (B) The peak parasitemia for each mouse group is represented as the
mean  the standard deviation (SD) (n  6). Asterisks denote that the parasitemia of mice from groups 3, 4, and 5 was significantly lower than
that of mice from groups 1 and 2 (P 	 0.01 in all cases). Mice from groups 4 and 5 had a significantly lower parasitemia than mice from group
3 (P 	 0.05). (C) The graph shows the Kaplan-Meier curves for survival of the mice groups immunized and challenged as described above (n 
9). Pooled results from two experiments are shown. Mice from group 3 survived significantly longer than animals from group 1 and 2 (P 	 0.0001
in both cases). Mice from groups 4 and 5 survived significantly longer than the other groups (P 	 0.0001 in all cases). (D) A/Sn mice were
immunized as described. Two weeks or 98 days after the final immunizing dose, mice were challenged i.p. with 150 bloodstream trypomastigotes.
(E) The parasitemia for each mouse group is represented as the mean  the SD (n  6). Asterisks indicate that ASP-2-vaccinated mice had a
significantly lower parasitemia (P	 0.01) than nonimmune animals. (F) The graph shows the Kaplan-Meier curves for survival of the mouse groups
immunized and challenged as described above (n  6). Mice from groups vaccinated with ASP-2 survived significantly longer than nonimmune
control animals (P 	 0.001). (G) A/Sn mice were immunized as described. Before and after challenge i.p. with 150 bloodstream trypomastigotes,
mice were treated as described in Materials and Methods with rat IgG or anti-CD4 MAb. (H) The parasitemia for each mouse group is represented
as the mean the SD (n 12). Asterisks indicate that ASP-2-vaccinated mice treated with rat IgG had a significantly lower parasitemia (P	 0.01)
than nonimmune animals or ASP-2-vaccinated mice treated with anti-CD4 MAb. (I) The graph shows the Kaplan-Meier curves for survival of
mouse groups immunized and challenged as described above (n  12). ASP-2-immunized mice treated with rat IgG survived significantly longer
than nonimmune animals or ASP-2-immunized mice treated with anti-CD4 MAb (P 	 0.0001 in both cases). ASP-2-immunized mice treated with
anti-CD4 MAb survived longer than nonimmune animals. The results are pooled from two independent experiments. (J) A/Sn mice
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98 days after infection survived longer than control animals
(Fig. 1F, P 	 0.001 in both cases). In addition, the mortality
rates of the mice vaccinated with ASP-2 were not statistically
different (P  0.05).
To determine whether this protective immunity was depen-
dent on CD4 or CD8 T cells, A/Sn mice vaccinated with the
heterologous prime-boost regimen (pIgSPCl.9/AdASP-2) were
treated with anti-CD4 or CD8 MAb prior to challenge with
bloodstream trypomastigotes. Treatment with anti-CD4 MAb
renders these mice more susceptible to infection. CD4-de-
pleted mice presented parasitemia similar to control mice in-
jected with pcDNA3/Ad
-gal (Fig. 1H). Although their mor-
tality rate was high (80%), they lived longer than control mice
(Fig. 1I, P 	 0.001).
Treatment with anti-CD8 MAb renders these mice com-
pletely susceptible to infection. CD8-depleted mice presented
parasitemia and survival rates similar to those of control mice
injected with pcDNA3/Ad
-gal (Fig. 1K and L). In contrast,
A/Sn mice vaccinated with a heterologous prime-boost regi-
men (pIgSPCl.9/AdASP-2) and treated with rat IgG had sig-
nificantly lower parasitemia and survived the otherwise lethal
challenge with T. cruzi.
The blood of AdASP-2-immunized animals were collected
and added to hemocultures. Parasites did not grow in any of
the samples, indicating a very low-grade parasitemia or the
absence of parasites. PCR analysis revealed that in fact some
mice had detectable parasite DNA. Comparing to known
amounts of parasite DNA equivalents, the DNA detected
ranged from 	12.5 to 50 per ml of blood (n  7, t  150 days
[data not shown]).
Perforin expression is required for maximal protective im-
munity following a heterologous prime-boost vaccination reg-
imen in C57BL/6 mice. In order to determine the presence of
ASP-2-specific cytotoxic T cells after immunization with the
different protocols, we performed an in vivo cytotoxicity assay
(57). For that reason, we used target cells coated with the
peptide TEWETGQI, which we had previously identified as an
immunodominant H-2Kk-restricted CD8 T-cell epitope (6, 19,
57, 58). The assay was performed in immunized A/Sn before or
13 days after challenge with bloodstream trypomastigotes. As
shown in Fig. 2, groups of mice immunized with recombinant
AdASP-2 presented in vivo cytotoxicity levels of20% before chal-
lenge. In contrast, immunization with two doses of pIgSPCl.9 failed
to elicit a significant degree of in vivo cytotoxicity.
After challenge with trypomastigotes, all mice groups immu-
nized with the asp-2 gene (plasmid or adenovirus) showed a
significant degree of in vivo cytotoxicity compared to control
animals injected with pcDNA3/Ad
-gal or naive mice. Animals
that received two doses of pIgSPCl.9 had slightly lower levels
of in vivo cytotoxicity, although these did not vary significantly
from the levels of the other groups.
These experiments were also performed in C57BL/6 mice
because we planned to use genetically modified mice in sub-
sequent experiments. In this mouse strain, we used target cells
coated with the immunodominant H-2Kb-restricted epitope
VNHRFTLV (57–59). The results essentially confirmed the
observations described above except that the levels of the in
vivo cytotoxicity were higher for this epitope (data not shown).
The fact that mice immunized with recombinant AdASP-2
showed the highest levels of in vivo cytotoxicity prior to chal-
lenge and some degree of protection (Fig. 1B and C) led us to
pursue our second goal: whether the perforin could be critical
to immunity elicited by vaccination.
were immunized as described. Before and after challenge i.p. with 150 bloodstream trypomastigotes, mice were treated as described in Materials and
Methods with rat IgG or anti-CD8 MAb. (K) The parasitemia for each mouse group is represented as the mean  the SD (n  6). Asterisks indicate
that ASP-2-immunized mice treated with rat IgG had a significantly lower parasitemia (P 	 0.01) than nonimmune animals or ASP-2-vaccinated mice
treated with anti-CD8 MAb. (L) The graph shows the Kaplan-Meier curves for survival of mouse groups immunized and challenged as described above
(n 8 to 9). ASP-2-immunized mice treated with rat IgG survived significantly longer (P	 0.0001) than nonimmune animals or ASP-2-immunized mice
treated with anti-CD8 MAb. The results are representative of two independent experiments.
FIG. 2. In vivo cytotoxic activity against target cells coated with a
peptide representing the CD8 epitope in mice immunized with differ-
ent protocols before or after challenge with T. cruzi. A/Sn mice were
injected with the different immunization protocols depicted at the side
of the charter. The immunizing doses were injected i.m. at 0 and 3
weeks. Two weeks after the final immunizing dose, half of the mice
were injected with splenic syngeneic cells labeled with CFSE and
coated with peptide TEWETGQI. The remaining half of the animals
was challenged i.p. with 150 blood forms of T. cruzi. Thirteen days
later, these mice were also injected with splenic syngeneic cells labeled
with CFSE and coated with the peptide TEWETGQI. The specific in
vivo cytotoxic activity was estimated after 20 h as described in Mate-
rials and Methods. Results are expressed as medians (bars), and each
dot represents an individual mouse. Symbols denote significantly
higher (P	 0.01) specific in vivo cytotoxic activity compared to control
naive or pcDNA-3/Ad
-gal injected mice prior to infection (asterisks)
or after a challenge with T. cruzi (crosses). The results are represen-
tative of experiments performed twice with similar results.
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In our earlier studies, we had observed that the in vivo
cytotoxicity against the ASP-2-derived epitope (VNHRFTLV)
was dependent on the presence of perforin since T. cruzi-
infected or adenovirus-immunized perforin KO mice failed to
eliminate peptide-coated cells in vivo (59; unpublished results).
Based on these observations, we performed protective im-
munity experiments following heterologous prime-boost
(pIgSPCl.9/AdASP-2) vaccination using perforin KO mice. Be-
cause these mice have a C57BL/6 genetic background, we had
to change our experimental model to C57BL/6 WT mice. After
the challenge with bloodstream trypomastigotes, ASP-2-vacci-
nated C57BL/6 WT mice had significantly lower peak para-
sitemia (20.47-fold reduction) than control mice injected with
pcDNA3/Ad
-gal (Fig. 3A, P	 0.001). All of the C57BL/6 WT
ASP-2-vaccinated mice survived, whereas 46% of the control
mice died (Fig. 3E, P 	 0.0001). After the challenge with
trypomastigotes, the ASP-2-vaccinated perforin KO mice ani-
mals still had a significantly lower peak parasitemia (4.93-fold
reduction) than control mice injected with pcDNA3/Ad
-gal
(Fig. 3B, P 	 0.001). Although vaccinated perforin KO mice
survived longer than the control perforin KO mice (P 	
0.0001), 92.3% of the challenged mice died (Fig. 3E). C57BL/6
WT ASP-2-vaccinated mice controlled better the peak para-
sitemia and survived longer than vaccinated perforin KO mice
(P 	 0.0001). These results indicated that perforin KO mice
are capable of developing some degree of protective immunity,
if assessed in terms of the reduction of peak parasitemia and
delayed mortality. However, it confirmed our hypothesis that
perforin expression is indeed critical for full protective immu-
nity and mouse survival following heterologous prime-boost
vaccination with pIgSPCl.9/AdASP-2.
To determine the participation of CD4 and CD8 T cells
in this mouse model, we performed CD4 depletion or used
CD8KO mice. We observed that animals vaccinated with
pIgSPCl.9/AdASP-2 and depleted of CD4 T cells prior to in-
fection still had a significantly lower peak parasitemia (10.94-
fold reduction) compared to control animals injected with
pcDNA3/Ad
-gal (Fig. 3C). However, only 30% of ASP-2-
vaccinated CD4-depleted mice survived, whereas 100% of the
control CD4-depleted animals died (Fig. 3F, P 	 0.001).
CD8 KO mice vaccinated with ASP-2 did not show any
specific reduction in the peak parasitemia (1.32-fold reduction)
compared to control mice injected with pcDNA3/Ad
-gal (Fig.
3D). Although ASP-2-vaccinated CD8 KO mice survived
longer than control CD8 KO mice (P 	 0.05), 87.5% of the
mice died (Fig. 3F). Compared to the CD4-depleted vacci-
nated mice, these mice were more susceptible (P  0.001),
suggesting that CD8 T cells are a slightly more important
during the effector phase.
Characterization of the cell-mediated immune responses in
immunized C57BL/6 WT and perforin KO mice. The fact that
vaccinated perforin KO mice were highly susceptible to infec-
tion prompted us to further analyze the cell-mediated immune
responses. When restimulated in vitro with the recombinant
protein His-65 kDa (10), splenic cells from vaccinated WT
mice secreted significantly higher amounts of IFN- than the
perforin KO animals (Fig. 4A). This cytokine secretion upon
stimulation with the soluble antigen reflects activation of
CD4 T cells because the presence of anti-CD4 MAb in cul-
FIG. 3. Trypomastigote-induced parasitemia and mortality in
C57BL/6 WT, perforin KO, CD4-depleted, or CD8 KO mice immu-
nized with the heterologous prime-boost regimen. C57BL/6 WT, per-
forin KO, CD4-depleted, or CD8 KO mice were immunized with
pIgSPCl.9, followed by AdASP-2 both injected i.m., at 0 and 3 weeks,
respectively. Control mice were injected with pcDNA3, followed by
Ad
-gal both injected i.m., at 0 and 3. Two weeks after the last
immunizing dose, mice were challenged i.p. with 104 bloodstream
trypomastigotes. (A to D) The parasitemia for each mouse group is
represented as the mean  the SD (n  5 to 8). Asterisks denote that
parasitemia was significantly lower (P 	 0.01) for ASP-2-vaccinated
mice (f) than for controls nonimmune mice (F). The results are
representative of experiments performed twice with similar results. (E
and F) The graphs show the Kaplan-Meier curves for survival of the
mouse groups immunized and challenged as described above (A to D).
For C57BL/6 WT and perforin KO mice, the total number of animals
was 13. In the case of CD4-depleted or CD8 KO mice, the number of
animals was 10 or 8, respectively. Statistical analysis showed that (i)
ASP-2-vaccinated C57BL/6 WT mice survived longer than all of the
other mouse groups (P 	 0.0001 in all cases), (ii) ASP-2-vaccinated
perforin KO mice survived longer than control nonimmune perforin
KO mice or CD8 KO mice (P 	 0.001 in both cases), (iii) ASP-2-
vaccinated CD4-depleted mice survived longer than control nonim-
mune CD4-depleted mice (P 	 0.001, and (iv) ASP-2-vaccinated CD8
KO mice survived longer than control nonimmune CD8 KO mice (P	
0.01).
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ture inhibited IFN- secretion by 80% (reference 10 and
data not shown).
We then characterized several functional and phenotypic
aspects of the specific CD8 T cells. Staining of the specific
CD8 T cells with the multimer H-2Kb/VNHRFTLV showed
that the frequency and total amounts of these cells in the
spleen were the same for perforin KO and C57BL/6 WT
mice vaccinated with the heterologous prime boost regimen
(Fig. 4B).
Because specific CD8 T cells secreted IFN- and granule-
associated proteins upon ex vivo stimulation with peptides, we
performed an ELISPOT assay and stained the splenic T cells
with antibodies to CD3, CD8, CD107a, and IFN- after in vitro
stimulation with peptide. The frequency of splenic IFN--pro-
ducing cells was 2.77 times higher in ASP-2-vaccinated
C57BL/6 WT than in perforin KO mice (Fig. 4C, P 	 0.001).
By FACS analysis, we found three populations of antigen-
reactive CD3 CD8 T cells. These cells were positive for
CD107a (a marker for T-cell degranulation and cytotoxicity
[3]) or IFN- or both. The comparison of the amount of
CD3CD8 T cells between vaccinated C57BL/6 WT and per-
forin KO mice showed a significantly higher number of cells
expressing both markers or IFN- only in the first group (Fig.
4D, P 	 0.05). This difference was also observed in CD3
CD8 T cells when we considered the total frequency of
CD107a expressing or not IFN- (P 	 0.01) but not CD107a
only (P  0.05). Considering that the total number of CD3
CD8 T cells stained with the multimer H-2Kb/VNHRFTLV
were similar, we concluded that the generation and/or matu-
ration of antigen-specific CD3CD8 T cells of perforin KO
mice expressing both markers or IFN- was selectively im-
paired.
Similar results were observed when we estimated the in vivo
cytotoxic activity against target cells coated with peptide
VNHRFTLV. C57BL/6 WT mice displayed higher cytotoxic
activity (two times or more) than vaccinated perforin KO mice
(Fig. 4E, P 	 0.01). This difference was slightly higher in short-
term elimination (4 h) than in long-term elimination (20 h).
Subsequently, we used ICS to evaluate the cytokines ex-
pressed by specific CD8 T cells after in vitro peptide stimu-
lation. The staining of CD3 CD8 splenic cells stimulated
with peptide in some cases was performed simultaneously with
antibodies to IFN-, TNF-, and IL-2. These cytokines are
regularly used to identify multifunctional T cells (28). The
number of peptide-specific T cells expressing any of these
cytokines was higher in ASP-2-immunized C57BL/6 WT mice
than in perforin KO mice. Most cytokine-producing CD3
CD8 T cells from ASP-2 immune C57BL/6 WT mice were
stained for IFN- (87%) or TNF- (58%) or both markers
(45%). The frequency of CD3 CD8 T cells stained for
IL-2 was only 7% and, for triple-stained cells, the frequency
was less than 5% (Fig. 5A, B, and C). The frequency of
CD3 CD8 T cells stained for either IFN- or TNF- was
reduced in splenic cells from ASP-2-vaccinated perforin KO
mice compared to C57BL/6 WT (Fig. 5A to D, P 	 0.05).
However, the most significant difference was observed in the
frequency of CD3 CD8 T cells simultaneously expressing
IFN- and TNF- after peptide stimulation. ASP-2 immune
C57BL/6 WT mice had 19-fold more double-positive CD8 T
cells than perforin KO mice (P 	 0.005). The frequency in the
FIG. 4. Cell mediated response of C57BL/6 WT or perforin KO mice
after immunization with the heterologous prime-boost vaccination regi-
men. C57BL/6 WT or perforin KO mice were immunized as described in
the legend of Fig. 3. Two weeks after the final immunizing dose, splenic
cells were restimulated in vitro in the presence of medium (Med), recom-
binant glutathione S-transferase (GST; 10 g/ml) or recombinant ASP-2
(His-65 kDa; 10 g/ml [A]). When we compared all mouse groups, ASP-
2-immunized WT spleens cells secreted more IFN- upon recombinant
protein stimulation (asterisk, P 	 0.05 in all cases). We estimated the
frequency of specific splenic cells by staining with anti-CD8 and the
multimer H-2Kb/VNHRFTLV (B) or the number of splenic IFN- spot-
forming cells (SFC) by the ex vivo ELISPOT assay (C). When we com-
pared groups of mice immunized with pIgSPCl.9/AdASP-2, immunized
C57BL/6 WT mice had a higher frequency of SFC than the immunized
perforin KO mice (asterisk, P	 0.001). Alternatively, these mice had their
splenic cells cultured in the presence of anti-CD28 and FITC-labeled
anti-CD107a, with or without the peptide VNHRFTLV. (D) After 12 h,
cells were stained with APC-labeled anti-CD8, fixed, permeabilized, and
stained with APC-Cy7-labeled anti-CD3, PE-Cy7-labeled anti-IFN-.
When we compared groups of mice immunized with pIgSPCl.9/AdASP-2,
immunized C57BL/6 WT mice had a higher frequency of CD3CD8 T
cells expressing either IFN- or double-stained for CD107a/IFN- than
the immunized perforin KO mice (asterisks, P	 0.01 in all cases). Finally,
we estimated the in vivo cytotoxic activity by injecting immunized mice
with CFSE-labeled splenic cells labeled with CFSE and coated with the
peptide VNHRFTLV. (E) After 4 or 20 h, the in vivo cytotoxic activity
was determined. When we compared groups of mice immunized with
pIgSPCl.9/AdASP-2, immunized C57BL/6 WT mice displayed signifi-
cantly higher in vivo cytotoxicity than perforin KO mice (asterisk, P	 0.01
in both cases). The results are expressed as medians (bars) and each
individual mouse (dots) and are representative of experiments performed
at least twice with similar results.
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total of responder cells was significantly higher (a fivefold
increase) in ASP-2 immune C57BL/6 WT mice than in perforin
KO mice (P 	 0.001). Again, considering that the total num-
bers of CD3 CD8 T cells stained with the multimer H-2Kb-
VNHRFTLV were similar, we concluded that the generation
and/or maturation of antigen-specific CD3CD8 T cells was
severely impaired among ASP-2 immune perforin KO mice
expressing either IFN- or TNF- or both cytokines simulta-
neously. Comparison of the mean fluorescence intensities of
the different cytokines with ICS failed to detect significant
differences between the distinct CD8 T cells subpopulations
or between WT and KO mice (data not shown).
Finally, we compared the surface markers expressed on pro-
tective ASP-2-specific splenic CD8 T lymphocytes elicited by
the heterologous prime-boost regimen (pIgSPCl.9/AdASP-2).
For that purpose, purified CD8 T cells obtained from im-
mune mice were triple stained with anti-CD8, multimer
H-2Kb/VNHRFTLV, and one of several different activation
markers. The fluorescence intensity was compared to the ex-
pression of these same activation markers on naive CD8 T cells.
FIG. 5. ICS of CD8 T cells from C57BL/6 WT or perforin KO mice immunized with the heterologous prime-boost vaccination regimen.
C57BL/6 WT or perforin KO mice were immunized with pcDNA3/Ad
-gal or pIgSPCl.9/AdASP-2. Fourteen days after the final immunizing dose,
these mice had their splenic cells cultured in the presence of anti-CD28 and brefeldin A, with or without the peptide VNHRFTLV. After 12 h,
cells were stained with APC-labeled anti-CD8, fixed, permeabilized, and stained with APC-Cy7-labeled anti-CD3, PE-Cy7-labeled anti-IFN-, and
Alexa 488-labeled anti-TNF-. (A and B) Examples of splenic CD3 CD8 cells from immunized C57BL/6 WT or perforin KO mice stained for
IFN- and TNF-. (C) Frequency of each cell population. Asterisks indicate that C57BL/6 WT mice immunized with IgSPCl.9/AdASP-2 had a
higher frequency of CD3 CD8 T cells expressing either IFN- or TNF- or both cytokines than perforin KO mice immunized with pIgSPCl.9/
AdASP-2 (P  0.01 in all cases). (D) We calculate the frequency of each cell population in relation to the total amount of cells expressing any
cytokine. An asterisk indicates that C57BL/6 WT mice immunized with of pIgSPCl.9/AdASP-2 had higher frequencies of CD3 CD8 T cells
expressing both IFN- and TNF- than perforin KO mice immunized with pIgSPCl.9/AdASP-2 (P 	 0.01 in all cases). A cross indicates that
perforin KO mice immunized with IgSPCl.9/AdASP-2 had a higher frequency of CD3 CD8 T cells expressing only IFN- than C57BL/6 WT
mice immunized with pIgSPCl.9/AdASP-2. The results are presented as medians (bars) and each individual mouse (dots) and are representative
of experiments performed twice with similar results.
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As shown in Fig. 6, the phenotype of double-stained CD8
H-2Kb/VNHRFTLV cells from immune C57BL/6 WT animals
was CD11ahigh CD43high CD44high CD62Llow CD127low. The ac-
tivation marker KLRG-1 reproducibly stained part of the cells
(60%). On the other hand,40% of the antigen-specific CD8
T cells did not express this marker on the surface.
The pattern of expression of these surface markers on CD8
specific T cells from ASP-2 immune perforin KO mice was
generally similar. Only two significant differences were repro-
ducibly noted: (i) the mean intensity fluorescence of CD44 was
lower on epitope-specific CD8 T cells from immune perforin
KO mice, and (ii) the frequency of specific CD8 T cells from
immune perforin KO mice expressing the activation marker
KLRG-1 was lower. The frequencies of specific CD8 T ex-
pressing KLRG-1 marker in individual mice were 56.12 
11.84 and 31.67  14.01%, respectively, in ASP-2 immune
C57BL/6 WT mice and perforin KO mice (n  4, P 	 0.05).
IFN- KOmice immunized with a heterologous prime-boost
vaccination regimen develop specific in vivo cytotoxicity but
are highly susceptible to infection. Our final goal was to de-
termine whether specific cytotoxicity mediated by CD8 T
cells could be elicited by the heterologous prime-boost vacci-
nation regimen in the absence of IFN-. If so, what would the
impact of the absence of this critical mediator of adaptive
immunity be on the protective immunity of vaccinated
C57BL/6? ASP-2-vaccinated IFN- KO mice developed high
levels of in vivo cytotoxicity (95%, Fig. 7A). After challenge
with bloodstream trypomastigotes, vaccinated IFN- KO mice
had a parasitemia and a survival rate similar to that of control
IFN- KO mice injected with pcDNA3/Ad
-gal (Fig. 7B and
C, respectively). All vaccinated and control mice succumbed to
challenge before the 20th day after challenge. These results
demonstrated that, in the absence of IFN-, specific cytotox-
icity mediated by CD8 T cells was not sufficient to retard or
reduce the parasitemia. Also, it did not delay mouse mortality,
suggesting an interdependence between perforin and IFN-
during protective immunity.
DISCUSSION
As the initial aim of our study, we established an effective
protocol of genetic vaccination with a heterologous prime-
boost regimen using plasmid DNA and recombinant replica-
tion defective adenovirus both expressing the ASP-2 antigen of
the human protozoan parasite Trypanosoma cruzi. This proto-
col was an improvement over others described earlier when we
used at least three doses of either plasmid DNA or recombi-
nant protein to achieve significant protective immunity (6, 17,
19, 60). The heterologous prime-boost vaccination was more
effective than two doses of plasmid DNA or a single dose of
recombinant adenovirus.
There was no significant improvement noted in the compar-
ison of the heterologous prime-boost regimen with two doses
of recombinant adenovirus, since both were highly effective in
our model. Nevertheless, this regimen may have a number of
advantages for the long-term development of genetic recom-
binant vaccines providing a simple solution to the problem of
widespread immunity to the human adenoviral vector type 5
(1). Priming immunization with plasmid DNA seems to be
sufficient for the subsequent expansion of the trans-gene spe-
cific CD8 T cells in recombinant adenovirus-boosted animals
(9). This expansion occurs even in animals with previous im-
munity to human adenovirus 5.
Hemocultures from these vaccinated mice were all negative
denoting either very low or absent parasitemia. This result is an
improvement compared to earlier studies in which we always
observed parasites in hemocultures among a certain percent-
age of the vaccinated A/Sn mice (6, 60). Our results from this
initial part of the study thus confirmed the findings and applied
earlier studies of vaccination against experimental simian im-
FIG. 6. Phenotypic characterization of splenic specific CD8 T cells
induced by immunization of C57BL/6 WT or perforin KO mice with
the heterologous prime-boost vaccination regimen. C57BL/6 WT or
perforin KO mice were immunized with pIgSPCl.9/AdASP-2. Four-
teen days after the final immunizing dose, these mice had their CD8
splenic cells purified and stained with APC-labeled anti-CD8, biotin-
labeled H-2Kb-VNHRFTLV, and the indicated marker-specific anti-
body labeled with FITC prior to analysis by FACS. The histograms
show the expression of the markers on CD8 H-2Kb-VNHRFTLV T
cells (blue lines) or control naive CD8 spleen cells (red lines). Rep-
resentative analyses from three or more mice studied are shown.
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munodeficiency virus and malaria infection to a human patho-
gen (2, 13, 14, 26, 33, 41).
Both CD4 and CD8 T cells accounted for nonredundant
mechanisms of immunity since the depletion of each one prior
to challenge renders the animals susceptible to infection. In
vaccinated mice without CD8 T cells, we observed a complete
lack of control of parasitemia in both mouse strains (A/Sn and
C57BL/6). Also, no delay in mouse mortality was seen in A/Sn
mice, denoting a critical role for this subpopulation during
immunity. In vaccinated C57BL/6 mice, we observed a slight
delay in mouse mortality, suggesting the presence of effector
non-CD8 immune cells. Whether they are in fact CD4 re-
mains to be investigated.
In CD4 T-cell-depleted mice we still observed a significant
delay in mouse mortality compared to nonimmune controls
compatible with a CD8 T-cel-mediated immunity. However,
the control of parasitemia was significantly better in C57BL/6
mice. Finally, the fact that CD4 and CD8 T cells interact
during the memory immune responses makes it more difficult
to evaluate precisely the effector and/or helper function of
CD4 T cells during a complex process such as protective
immunity in different experimental models. For that purpose
more complex experimental systems will have to be developed.
In the second part of our study, we characterized the impor-
tance of perforin during protective immunity elicited by DNA
prime adenovirus-boost vaccination. We observed that ASP-2-
vaccinated perforin KO mice developed only limited immunity
to the infection that did not prevent death.
Detailed analysis of the specific immune response revealed
an impaired IFN- secretion by immune spleen cells. Although
perforin deficiency did not impair the expansion of splenic
specific CD8 T cells, these cells had a significantly lower
frequency of specific CD107a/IFN- or IFN-/TNF-
cells after in vitro restimulation. Also, the in vivo cytotoxicity
was reproducibly reduced. Nevertheless, it is noteworthy that
the in vivo cytotoxicity was present at certain levels in the
perforin KO mice, indicating the presence of a perforin-inde-
pendent mechanism(s) of lysis (TNF-, FasL, etc.) yet to be
identified. Finally, the pattern of expression of certain surface
markers on CD8 specific T cells from immune perforin KO
mice were significantly different (CD44 and KLRG-1).
Earlier studies on the characteristics of specific CD8 T cells
in perforin-deficient mice indicated a dual function for this
molecule during the homeostasis and effector phases of the
immune response. In different reports (including ours), no
significant modification was observed in the expansion of spe-
cific CD8 T cells as estimated by the multimer staining (5, 15,
16). In contrast, an increase in the number of peptide-specific
cytokine-expressing CD8 T cells was noted among these KO
mice in certain studies (7, 64). Those authors provided evi-
dence that perforin-mediated lyses of antigen-presenting cells
could account for a restriction in the expansion of specific
CD8 T cells (64). Equally important, it was also noted that
during certain chronic viral infection, perforin-mediated down-
regulation of T-cell responses is critical to avoiding autoimmu-
nity and immune-pathological damages (40). To date, the most
predictable immunological impairment of the perforin KO
mice has been the reduced level of cytotoxicity (in vivo or in
vitro) reported by distinct groups, including ours (8, 15, 32, 59).
Based on other experimental human parasitic infections, it
was not possible to predict that perforin expression would be in
fact critical to the protective immunity against T. cruzi infection
observed after DNA-prime adenovirus-boost vaccination.
Compared to C57BL/6 WT mice, perforin KO mice are not
more susceptible to infections with the intracellular protozoan
parasites Toxoplasma gondii or Plasmodium berghei (20, 47).
The fact that perforin-deficient CD8 T cells efficiently elim-
inate liver stages of malaria parasites is very important (46).
There is a single report stating that perforin deficiency abro-
gates protective immunity against Leishmania amazonensis in-
FIG. 7. In vivo cytotoxic activity against target cells coated with
peptides representing the CD8 epitope and trypomastigote-induced
parasitemia and mortality of IFN- KO mice immunized with heter-
ologous prime-boost regimen. IFN- KO mice were immunized as
described in the legend of Fig. 3. (A) Two weeks after the final
immunizing dose, mice were injected with splenic syngeneic cells la-
beled with CFSE and coated with the peptide VNHRFTLV. The
specific in vivo cytotoxic activity was estimated after 20 h as described
in Materials and Methods. The results are expressed as medians (bars)
and each individual mouse (dots, n  3). An asterisk denotes signifi-
cantly higher (P 	 0.01) specific in vivo cytotoxic activity of ASP-2-
immunized IFN- KO mice than control pcDNA-3/Ad
-gal-injected
mice. (B) Two weeks after the final immunizing dose, mice were
challenged i.p. with 104 bloodstream trypomastigotes. The parasitemia
for each mouse group is represented as mean  the SD (n  6).
(C) The graph shows the Kaplan-Meier curves for survival of the mice
groups immunized and challenged as described above (n  6). These
experiments were performed twice with similar results.
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fection elicited by vaccination with a recombinant protein (18).
Therefore, we believe that the fact that perforin is critical to
our system may help us to understand the role of this molecule
in resistance to human parasitic infections.
The fact that perforin can be expressed in other cell types of
the adaptive or innate immune system does not allow us to
conclude that its expression on CD8 T cells is the single
restricting factor in our system. Other types of specific lym-
phocytes that may express perforin are CD4 T cells (61, 63).
We observed that in our vaccination strategy CD4 T cells
were important for T. cruzi immunity after infection of A/Sn
and C57BL/6. CD8 KO mice were more susceptible than per-
forin KO mice, indicating the presence of a non-perforin-
mediated mechanisms mediated by these cells.
Other cell types may play important roles in mice immunity
against T. cruzi infection. Natural killer (NK) cells have been
described as mediators of natural resistance to T. cruzi exper-
imental infection. The depletion of NK cells by treatment with
polyclonal anti-asialo GM1 renders animals more susceptible
to infection (24). However, these cells are thought to act early,
secreting IFN- (11, 52). A role for cytolysis mediated by
perforin has been discarded during NK direct contact-medi-
ated lysis of T. cruzi or T. cruzi-infected cells (35, 36). The role
of NK cells in our system remains to be studied.
CD1d-restricted NKT cells also have been described as ca-
pable of improving the resistance to T. cruzi infection (22–24).
Immunization of CD1d KO mice that fail to express NKT cells
allowed us to test whether NKT cells are involved in immunity
in our vaccination regimen. We found that following heterol-
ogous prime-boost immunization, these mice developed pro-
tective immunity similar to C57BL/6 WT mice (B. C. G. de
Alencar and M. M. Rodrigues, unpublished data). Based on
this result, these cells are clearly not involved in the develop-
ment of protective immunity after vaccination. Finally,  T
cells are also not clearly associated with protective immunity
during experimental T. cruzi infection (12, 51).
Based on these observations and the fact that CD8 T cells
are critical for mouse survival after experimental vaccination
and infection, we consider it plausible that these cells represent
a major, but not the single, source of perforin in our system.
Perforin mediates this function, allowing the full maturation of
effector CD8 T cells. The correlation between protective im-
munity and the presence of specific CD8 T cells expressing
CD107a/IFN- or IFN-/TNF- simultaneously is im-
portant to defining the type of CD8 T cells that should be
generated during vaccination protocols. Up to now, vaccine
studies aimed at determining immunity have relied heavily on
the detection of the number of CD8 T-cell using multimer
staining or IFN- production (ELISPOT or ICS). However, as
we established, these may not be the best criteria for deter-
mining the presence of immune protective CD8 T cells. Al-
though we can observe reproducible differences in the number
of peptide-specific IFN--producing cells by ELISPOT assay,
we considered that the presence of double positive for IFN-/
TNF- or IFN-/CD107a was more accurate to estimate the
protective immunity in our model of vaccination.
The final goal of our study was to define whether the in vivo
cytotoxic activity prior to challenge would ensure protective
immunity in the absence of IFN-, an important mediator of
adaptive immunity during experimental T. cruzi infection. We
concluded from experiments using IFN- KO mice that this
cytokine is critical even in the presence of high levels of in vivo
cytotoxicity. IFN- KO C57BL/6 mice were more susceptible
than CD4-depleted or CD8 KO animals, indicating that IFN-
most likely come from both sources.
A possible role for antibodies during the protective immu-
nity response we observed is highly unlikely. ASP-2 is ex-
pressed only by intracellular amastigotes or it is not accessible
to antibodies in the other forms of the parasite (10, 17). Also,
immune sera or MAbs incubated with parasites are not able to
neutralize their infectivity in vivo (M. M. Rodrigues, unpub-
lished results).
In summary, we provide evidences that CD4 and CD8
T-cell mediated immunity elicited by the DNA-prime recom-
binant adenovirus-boost vaccination requires both perforin
and IFN-. The implications are that in the case of T. cruzi
infection, in addition to the number of specific cells (multimer
staining) and IFN- production (ELISPOT assay), other pa-
rameters, such as the presence of double-positive IFN-/
TNF- or IFN-/CD107a or perforin-dependent cytotoxicity,
might be crucial to determining whether immune protective T
cells are present during infection in preclinical or clinical vac-
cination trials.
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